Reagent Generation for Bioanalytical Method Development on Biologics
ID: 75N95025R00007Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Medicinal and Botanical Manufacturing (325411)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/62ef1e103af0403db54b9fdbb745a5e5/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Reagent Generation for Bioanalytical Method Development on Biologics
    Currently viewing
    Sources Sought
    Similar Opportunities
    CRO Support for NCATS Bioanalytical Method Development for Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified contractors to provide support for bioanalytical method development for biologics under a Sources Sought notice. The primary objective is to identify capable organizations that can develop and validate bioanalytical methods for quantitative analyses of novel therapeutic biologics and anti-drug antibodies in various biological matrices, as well as manage project administration and quality assurance. This initiative is crucial for advancing drug development processes and ensuring compliance with regulatory standards, ultimately facilitating the transition of therapeutic candidates to clinical trials. Interested parties must submit their capability statements and relevant information by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov.
    Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is planning to award a Firm-Fixed price purchase order for various reagents and consumables necessary for clinical patient care testing at the NIH Clinical Center. The procurement is intended to secure proprietary products from Life Technologies Corporation, which are essential for diagnosing and monitoring hematological disorders, ensuring compliance with regulatory standards, and maintaining the integrity of laboratory operations. Interested vendors capable of providing equivalent products are invited to submit capability statements by the specified deadline, with inquiries directed to Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov. The acquisition will adhere to the simplified acquisition threshold and is being conducted under FAR Subpart 13.106-1(b)(i) for sole source procurement.
    Reagent Dispenser
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking information on domestically manufactured reagent dispensers through a Sources Sought notice. The procurement aims to identify U.S.-made products that meet stringent specifications, including features such as custom plate addition, high precision peristaltic pumping, and a dispensing volume capacity ranging from 0.5 to 2500μl, among others. This initiative underscores the importance of domestic manufacturing in scientific and medical instrumentation, aligning with the Buy American Act and Executive Order 14005. Interested vendors must submit their capability statements by October 25, 2024, to Kelly Lowe at kelly.lowe@nih.gov, ensuring compliance with the outlined requirements and confidentiality stipulations.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences (NCATS), is seeking qualified small businesses to provide Chemistry, Manufacturing, and Controls (CMC) and related services for the development of drug products. The objective of this procurement is to support the Therapeutic Development Branch in ensuring the delivery of drug products of sufficient quality and quantity for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic candidates through the drug development pipeline. This opportunity is part of a Small Business Sources Sought notice, aimed at gathering information on the capabilities of small businesses to fulfill these requirements, with a focus on compliance with applicable regulations and the potential for a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Interested vendors must submit their capability statements by 10:00 AM Eastern Time on July 21, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances, as outlined in RFP Number 75N95024R00094. The primary objective is to ensure the provision of high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, which are critical for advancing therapeutic innovations. This opportunity emphasizes compliance with current Good Manufacturing Practices (cGMP) and requires detailed reporting and documentation throughout the contract period. Interested contractors should note that the proposal submission deadline is December 3, 2024, with a maximum funding amount of $49.7 million anticipated for the contract period from September 1, 2025, to May 14, 2031. For further inquiries, potential bidders can contact Samson Shifaraw at samson.shifaraw@nih.gov or Valerie Whipple at valerie.whipple@nih.gov.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under Request for Proposal (RFP) No. 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, regulate, and distribute a variety of drug compounds essential for advancing research on drug abuse and addiction, including controlled and uncontrolled substances such as morphine, methadone, and various cannabinoid preparations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, is crucial for supporting the drug abuse research community by ensuring the availability of authentic drug products while adhering to federal regulations. Proposals must be submitted electronically by November 15, 2024, and interested parties can contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.
    Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract for reagents and consumables to STEMCELL Technologies Inc. for use with the RoboSep™-S Cell Separator Systems at the NIH Clinical Center in Bethesda, Maryland. The procurement includes specific items such as the EasySep HLA Chimerism WB Myeloid Positive Selection kit, the EasySep HLA Chimerism WB CD3 Positive Selection kit, and RoboSep Filter Tip Racks, which are critical for separating cell populations in allogeneic transplant patients to assess engraftment status. Interested vendors capable of providing equivalent products may submit a capability statement by the specified deadline, with inquiries directed to Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov. The acquisition falls under NAICS code 325414, and the total purchase order will not exceed the simplified acquisition threshold.
    BD Biosciences BD FACSLyric™ 3L10C Lease, Consumables and Service
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) is seeking qualified contractors to provide leasing, consumables, and maintenance services for the BD FACSLyric™ 3L10C system, as part of a sources sought announcement. The procurement aims to ensure the continued operation of critical laboratory equipment used for immunology flow cytometry, which is essential for delivering over one million test results annually for patient care and research. This opportunity emphasizes the need for proprietary reagents and robust support from the manufacturer, highlighting the importance of consistent and reliable testing in a clinical research environment. Interested parties must submit their responses by 12:00 PM Eastern Standard Time on October 23, 2024, to the primary contact, Kimala Winfield, at kimala.winfield@nih.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the NIAID Clinical Products Center (CPC) contract, aimed at supporting clinical trials focused on immunologic, infectious, and allergic diseases. The contract will provide essential pharmacy and pharmaceutical oversight for national and international clinical trials, ensuring product integrity, participant safety, and compliance with regulatory standards, while also expanding support for additional NIH-funded trials and emergency public health programs as needed. This initiative is critical for advancing research in various immune-mediated diseases, including asthma, autoimmune disorders, and organ transplant rejection. Interested parties should prepare to submit proposals electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the presolicitation notice expected to be published on or around October 18, 2024. For further inquiries, contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.